Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- GLMD
- Price
- 0.85
- Stock movement up
- +0.04 (4.68%)
- Company name
- Galmed Pharmaceuticals Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 4.67M
- Ent value
- 3.83M
- Price/Sales
- -
- Price/Book
- 0.24
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -45.91%
- 1 year return (CAGR)
- -70.28%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
GLMD does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.24 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 5.48M |
| EPS (TTM) | -1.59 |
| FCF per share (TTM) | -1.16 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -7.11M |
| Net income (TTM) | -8.70M |
| EPS (TTM) | -1.59 |
| EPS (1y forward) | -0.85 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 3.31M |
| Net receivables | 549.00K |
| Total current assets | 19.72M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 21.58M |
| Accounts payable | 1.67M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 2.47M |
| Total liabilities | 2.47M |
| Shareholder's equity | 19.11M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -6.34M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -6.34M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -45.52% |
| Return on Assets | -40.31% |
| Return on Invested Capital | -45.52% |
| Cash Return on Invested Capital | -33.17% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.81 |
| Daily high | 0.85 |
| Daily low | 0.80 |
| Daily Volume | 72K |
| All-time high | 3232.80 |
| 1y analyst estimate | 12.00 |
| Beta | 0.30 |
| EPS (TTM) | -1.59 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 1 Apr 2026 |
Downside potential
Loading...
Downside potential data
| GLMD | S&P500 | |
| Current price drop from All-time high | -99.97% | -0.89% |
| Highest price drop | -99.98% | -19.00% |
| Date of highest drop | 31 Dec 2025 | 8 Apr 2025 |
| Avg drop from high | -99.94% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
4.67M
Marketcap category
Small-cap
Description
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Employees
3
Website
Investor relations
-
SEC filings
CEO
Allen Baharaff
Country
USA
City
Tel Aviv
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page